Parkinson’s disease (PD), the second most common age-related neurodegenerative disease, results from the loss of dopamine neurons in the substantia nigra. This disease is characterized by cardinal non-motor and motor symptoms. Several studies have demonstrated that neuropeptides, such as ghrelin, neuropeptide Y, pituitary adenylate cyclase-activating polypeptide, substance P, and neurotensin, are related to the onset of PD. This review mainly describes the changes in these neuropeptides and their receptors in the substantia nigra-striatum system as well as the other PD-related brain regions. Based on several in vitro and in vivo studies, most neuropeptides play a significant neuroprotective role in PD by preventing caspase-3 activation, decreasing mitochondrial-related oxidative stress, increasing mitochondrial biogenesis, inhibiting microglial activation, and anti-autophagic activity. Thus, neuropeptides may provide a new strategy for PD therapy.
Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic neurons in the substantia nigra and leads to progressive motor dysfunction. While studies have focused on the basal ganglia network, recent evidence suggests neuronal systems outside the basal ganglia are also related to PD pathogenesis. The zona incerta (ZI) is a predominantly inhibitory subthalamic region for global behavioral modulation. This study investigates the role of GABAergic neurons in the ZI in a mouse model of 6-hydroxydopamine (6-OHDA)-induced PD. First, we found a decrease in GABA-positive neurons in the ZI, and then the mice used chemogenetic/optogenetic stimulation to activate or inhibit GABAergic neurons. The motor performance of PD mice was significantly improved by chemogenetic/optogenetic activation of GABAergic neurons, and repeated chemogenetic activation of ZI GABAergic neurons increased the dopamine content in the striatum. Our work identifies the role of ZI GABAergic neurons in regulating motor behaviors in 6-OHDA-lesioned PD model mice.
The lateral habenula (LHb) and the rostromedial tegmental nucleus (RMTg) are critical brain structures involved in reward processing, aversive signaling, and mood regulation. Recent research has uncovered significant progress in understanding their physiological functions, neural circuits, and implications in neuropsychiatric disorders. By integrating signals from the limbic system and projecting into the midbrain monoaminergic system, the LHb encodes negative reward prediction error and mediates behaviors associated with depressive as well as stress response. Its overactivation can inhibit dopamine release, resulting in anhedonia. As the main downstream target of LHb, the RMTg exerts inhibitory control over dopaminergic neurons in the ventral tegmental area (VTA) via γ-aminobutyric acid (GABA), and participates in reward inhibition, addiction withdrawal and hyperalgesia regulation. The LHb activates GABAergic neurons within the RMTg through glutaminergic projection, thereby inhibiting dopamine release in the VTA neurons. This neuronal circuitry is critically involved in the pathophysiological mechanisms of depression, addiction and other neuropsychiatric disorders. Here, we reviewed the anatomical features and molecular markers of both LHb and RMTg along with their inputs, outputs and physiological functions of LHb and RMTg. This research is of great significance for understanding the neural mechanisms underlying neuropsychiatric diseases.